Login Register Cart 0
Generic placeholder image

Current Biotechnology

Editor-in-Chief

ISSN (Print): 2211-5501
ISSN (Online): 2211-551X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Current Review of Systemic Lupus Erythematosus Treatment Using Monoclonal Antibodies

Author(s): Rohan G. Shinde*, Vipul P. Patel, Shwetarani D. Gundgole, Suchita S. Dhumale and Snehal D. Dhole

Volume 11, Issue 1, 2022

Published on: 08 June, 2022

Page: [27 - 31] Pages: 5

DOI: 10.2174/2211550111666220329183309

Price: $65

conference banner
Abstract

Lupus is a heterogeneous and inflammatory autoimmune disease that affects the immune system of the body. This disease affects multiple tissues and organs. The most frequent kind of lupus is systemic lupus erythematosus (SLE). SLE is an autoimmune illness in which the immune system targets the body's tissues, resulting in extensive inflammation and tissue destruction in the organs involved. Joints, skin, brain, lungs, kidneys, and blood vessels can all be affected. It appears to be a form of B-cell disease in which autoantibodies attack the cells. Systemic lupus erythematosus autoimmune diseases involve different treatment methods. These abnormalities are due to the presence of autoantibodies, and these contribute to the degeneration of the body’s immune system. In this review, we will focus on various therapies, including SLE treatments, such as B-cell therapy, cytokine therapy, interferon targets, and anticomplementary therapies, all of which have become challenging. We will also discuss post-marketing use and ongoing clinical trials, as well as safety and effective doses.

Keywords: Lupus, autoimmune disease, monoclonal antibodies, benlysta, B-cell treatment, interleukin.

« Previous Next »
Graphical Abstract

[1]
Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001; 357(9261): 1027-32.
[http://dx.doi.org/10.1016/S0140-6736(00)04239-2] [PMID: 11293608]
[2]
Boumpas DT, Austin HA, Fessler BJ, et al. Systemic lupus erythematosus: Emerging concepts. Part 1: Renal, neuropsychiatric, cardiovas-cular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122(12): 940-50.
[3]
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377(9767): 721-31.
[http://dx.doi.org/10.1016/S0140-6736(10)61354-2] [PMID: 21296403]
[4]
Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314(10): 614-9.
[http://dx.doi.org/10.1056/NEJM198603063141004] [PMID: 3511372]
[5]
Galarza C, Valencia D, Tobon GJ, et al. Should rituximab be cosidered as a first choice treatment forsever autoimmune rheumatic disease. Clin Rev Allergy Immunol 2008; (34): 124-8.
[6]
Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67(3): 330-4.
[http://dx.doi.org/10.1136/ard.2007.079095] [PMID: 17827182]
[7]
Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67(12): 1724-31.
[http://dx.doi.org/10.1136/ard.2007.083162] [PMID: 18250115]
[8]
Clowse MEB, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severly active systemic lupus erythemato-susus. Arthritis Rheumatol 2017; (69): 362-75.
[http://dx.doi.org/10.1002/art.39856] [PMID: 27598855]
[9]
Boyce EG, Fusco BE. Belimumab: Review of use in systemic lupus erythematosus. Clin Ther 2012; 34(5): 1006-22.
[http://dx.doi.org/10.1016/j.clinthera.2012.02.028] [PMID: 22464040]
[10]
Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; (293): 2109-11.
[11]
Yan N, Seshasayee D. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002; (17): 515-24.
[12]
Tackey E, Lipsky PE, Illei GG, et al. Rationale for interleukin-6 blockade in systemic lupus erythematosusus. Lupus 2004; 13(5): 339-43.
[13]
urnberg WN, Schadendorf D, Czarnetzki BM. Interleukin-6 expression in the skin of patients with lupus erythematosusus. Exp Dermatol 1995; 4(1): 52-7.
[14]
Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomaekers in systemic lupus erythematosusus. 2007461-466. J Clin Immunol 2007; 27(5): 461-6.
[http://dx.doi.org/10.1007/s10875-007-9104-0]
[15]
Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies de-lays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179(1): 305-10.
[http://dx.doi.org/10.1084/jem.179.1.305] [PMID: 8270873]
[16]
Suh CH, Kim HA. Cytokines and their receptors as biomarkers of systemic lupus erythematosus. Expert Rev Mol Diagn 2008; 8(2): 189-98.
[http://dx.doi.org/10.1586/14737159.8.2.189] [PMID: 18366305]
[17]
Petri M, Wallace DJ, Spindler A, et al. Sifalimuab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosusus: A phase 1 randomized, controlled, doseescalation study. Arthritis Rheumatol 2013; 65(4): 1011-21.
[18]
Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355(12): 1233-43.
[http://dx.doi.org/10.1056/NEJMoa061648] [PMID: 16990386]
[19]
Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97(9): 2063-73.
[http://dx.doi.org/10.1172/JCI118643] [PMID: 8621796]
[20]
Folzenlogen D, Hofer MF, Leung DY, Freed JH, Newell MK. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol 1997; 83(3): 199-204.
[http://dx.doi.org/10.1006/clin.1997.4353] [PMID: 9175908]
[21]
Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human sys-temic lupus erythematosus. J Exp Med 1995; 181(3): 839-44.
[http://dx.doi.org/10.1084/jem.181.3.839] [PMID: 7869046]
[22]
Dörner T, Heimbächer C, Farner NL, Lipsky PE. Enhanced mutational activity of Vkappa gene rearrangements in systemic lupus erythe-matosus. Clin Immunol 1999; 92(2): 188-96.
[http://dx.doi.org/10.1006/clim.1999.4740] [PMID: 10444363]
[23]
Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996; 98(11): 2549-57.
[http://dx.doi.org/10.1172/JCI119073] [PMID: 8958217]
[24]
Tamimoto Y, Horiuchi T, Tsukamoto H, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans’ syndrome: Immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 2008; 47(6): 821-7.
[http://dx.doi.org/10.1093/rheumatology/ken071] [PMID: 18397955]
[25]
Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165(10): 5970-9.
[http://dx.doi.org/10.4049/jimmunol.165.10.5970] [PMID: 11067960]
[26]
Anolik J, Sanz I. B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16(5): 505-12.
[http://dx.doi.org/10.1097/01.bor.0000133660.52599.f6] [PMID: 15314486]
[27]
Tieng AT, Peeva E. B-cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38: 218-27.
[28]
Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58(1): 79-88.
[http://dx.doi.org/10.2165/00003495-199958010-00009] [PMID: 10439931]
[29]
Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004; 45(2): 205-19.
[http://dx.doi.org/10.1080/1042819031000139666] [PMID: 15101704]
[30]
Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101(3): 1045-52.
[http://dx.doi.org/10.1182/blood-2002-06-1761] [PMID: 12393541]
[31]
Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101(3): 949-54.
[http://dx.doi.org/10.1182/blood-2002-02-0469] [PMID: 12393572]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy